Clinical Trial Finder

Many patients with cardiomyopathy are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

Safety and Exploratory Efficacy Study of UCMSCs in Patients With Ischemic Heart Disease (SEESUPIHD)

Conditions:   Acute Myocardial Infarction;   Myocardial Infarction;   Ischemic Cardiomyopathy
Intervention:   Biological: umbilical cord mesenchymal stem cells
Sponsors:   Academy Military Medical Science, China;   Sun Yat-sen University
Not yet recruiting - verified October 2015

Training-induced Increased Left Ventricular Trabeculation

Conditions:   Athletes Heart;   Left Ventricular Hypertrabeculation
Sponsors:   St George's, University of London;   Barts Heart Centre;   Cardiac Risk in the Young;   British Heart Foundation
Not yet recruiting - verified September 2015

Adapted Physical Activity Effect on Aerobic Function and in Patients in Pre Liver Transplantation

Condition:   Motor Activity
Intervention:   Other: Physical activity
Sponsor:   University Hospital, Limoges
Not yet recruiting - verified September 2015

The Cardio-Oncology Breast Cancer Study

Conditions:   Cardiotoxicity;   Cardiomyopathies;   Breast Cancer
Intervention:   Other: Subclinical cardiotoxicity surveillance and treatment
Sponsor:   Karolinska University Hospital
Recruiting - verified October 2015

Non-invasive Evaluation of Myocardial Stiffness by Elastography

Condition:   Diastolic Heart Failure
Interventions:   Procedure: elastography function ShearWave Imaging;   Procedure: MRI
Sponsors:   French Cardiology Society;   Institut National de la Santé Et de la Recherche Médicale, France
Recruiting - verified October 2015

Safety & Efficacy of Intramyocardial Injection of Mesenchymal Precursor Cells on Myocardial Function in LVAD Recipients

Conditions:   Heart Failure;   Cardiomyopathy;   Ventricular Dysfunction
Interventions:   Biological: MPC Intramyocardial Injection;   Drug: Control Solution
Sponsors:   Annetine Gelijns;   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified September 2015

ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)

Condition:   Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)
Interventions:   Drug: Revusiran (ALN-TTRSC);   Drug: Sterile Normal Saline (0.9% NaCl)
Sponsor:   Alnylam Pharmaceuticals
Recruiting - verified September 2015

The Vital Amyloidosis Study, a Phase 3, Multicenter Efficacy and Safety Study of NEOD001

Condition:   Primary Systemic (AL) Amyloidosis
Interventions:   Drug: NEOD001;   Other: Placebo
Sponsor:   Prothena Therapeutics Ltd.
Recruiting - verified September 2015

MOMENTUM 3 IDE Clinical Study Protocol

Condition:   Advanced Refractory Left Ventricular Heart Failure
Interventions:   Device: HeartMate 3 LVAS;   Device: HeartMate II LVAS
Sponsor:   Thoratec Corporation
Recruiting - verified September 2015

18F-deoxyglucose (FDG) PET-CMD

Condition:   Patients With Idiopathic Dilated Cardiomyopathy
Intervention:   Drug: 18F-deoxyglucose (FDG)
Sponsor:   Nantes University Hospital
Recruiting - verified October 2015

Quantitative Detection of Circulating Donor-Specific DNA in Organ Transplant Recipients (DTRT-Multi-Center Study)

Conditions:   Cardiovascular Disease;   Acute Rejection of Cardiac Transplant;   Cardiac Transplant Rejection;   Heart Transplant Failure and Rejection
Sponsors:   Medical College of Wisconsin;   National Heart, Lung, and Blood Institute (NHLBI);   Columbia University;   Duke University;   University of Arkansas;   Emory University;   Children's Healthcare of Atlanta;   Vanderbilt University;   TAI Diagnostics, Inc.
Recruiting - verified September 2015

Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM

Condition:   Hypertrophic Cardiomyopathy
Interventions:   Drug: Valsartan;   Drug: Placebo
Sponsors:   New England Research Institutes;   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified July 2013

Burden of Disease Study In Patients With Transthyretin Familial Amyloidosis Polyneuropathy (TTR-FAP) orTransthyretin Cardiomyopathy (TTR-CM) And Caregivers

Conditions:   Transthyretin Familial Amyloidosis Polyneuropathy (TTR-FAP);   Transthyretin Cardiomyopathy (TTR-CM);   Familial Amyloid Cardiomyopathy;   Senile Systemic Amyloidosis (SSA)
Interventions:   Other: No drug;   Other: No drug
Sponsor:   Pfizer
Completed - verified October 2015

Cardiac Sarcoidosis Multi-Center Prospective Cohort

Condition:   Cardiac Sarcoidosis
Sponsors:   Ottawa Heart Institute Research Corporation;   Ontario Ministry of Health and Long Term Care;   Canadian Institutes of Health Research  (CIHR)
Recruiting - verified September 2015

Fabry and Cardiomyopathy (FaCard) Epidemiological Study for the Analysis of Biomarkers and the Clinical Course of Patients With Fabry Disease and the N215S-mutation

Conditions:   Cerebrovascular Accident;   Stroke, Acute;   Cerebral Stroke
Sponsor:   University of Rostock
Recruiting - verified October 2015

Congenital Muscle Disease Study of Patient and Family Reported Medical Information

Conditions:   Muscular Dystrophy;   Congenital Muscular Dystrophy;   Fukutin-related Protein Gene;   Limb Girdle;   FKRP Gene;   Childhood Onset LGMD;   Adult Onset LGMD;   POMT1;   POMT2;   POMGnT1;   LARGE;   Alpha Dystroglycan;   Dystroglycanopathy;   Centronuclear;   Multiminicore;   Multicore;   Minicore;   Congenital Fiber Type Disproportion;   Myotubular;   Nemaline;   Congenital Myopathy;   Neuromuscular;   Rigid Spine;   Phenotype-Genotype Correlation;   Cough Assisted Device;   Neuromuscular Disease;   Respiratory Exacerbation;   Invasive Ventilation;   Chest Physiotherapy;   Congenital Myopathies;   Genetic Mutations;   Hypertrophic Cardiomyopathy;   Wheelchair Use;   Cataract;   Opthalmoplegia;   Ullrich Congenital Muscular Dystrophy;   Intermediate Collagen VI Myopathy;   Laminin Alpha 2 Related Congenital Muscular Dystrophy;   MDC1A;   Merosin Deficient Congenital Muscular Dystrophy;   Congenital Muscular Dystrophy Undiagnosed;   Congenital Muscular Dystrophy Merosin Positive;   Walker Warburg Syndrome;   Muscle Eye Brain Disease;   Fukuyama;   Integrin Alpha 7 Deficiency;   Integrin Alpha 9 Deficiency;   Laminopathy;   Lamin AC;   SEPN 1 Related Myopathies;   Bethlem Myopathy;   Dystroglycanopathies;   LGMD2K;   LGMD2I;   LGMD2L;   LGMD2N;   Actin Aggregation Myopathy;   Cap Disease;   Central Core Disease;   Centronuclear Myopathy;   Core Rod Myopathy;   Hyaline Body Myopathy;   Multiminicore Myopathy;   Myotubular Myopathy;   Nemaline Myopathy;   Tubular Aggregate Myopathy;   Zebra Body Disease Myopathy;   Congenital Myopathy Other;   Reducing Body Myopathy;   Sarcotubular Myopathy;   Spheroid Body Myopathy
Sponsor:   Cure CMD
Recruiting - verified October 2015

Reduced Contractile Reserve: a Therapeutic Target in Heart Failure With Preserved Ejection Fraction(HFpEF)

Conditions:   Heart Failure With Preserved Ejection Fraction;   Pulmonary Disease;   Left Ventricular Hypertrophy/Hypertension
Interventions:   Drug: Dobutamine;   Drug: Amlodipine
Sponsors:   University of Wisconsin, Madison;   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified October 2015

Study of the Effect of SNPs in p53 and p53 Response Elements on the Inflammatory Response to DNA Damage

Conditions:   Inflammation;   Cancer;   Cardiomyopathy
Sponsor:   National Institute of Environmental Health Sciences (NIEHS)
Enrolling by invitation - verified December 2014

Study of Exercise Training in Hypertrophic Cardiomyopathy

Condition:   Cardiomyopathy, Hypertrophic
Intervention:   Behavioral: Exercise training
Sponsors:   University of Michigan;   Stanford University
Active, not recruiting - verified October 2015

Safety And Efficacy Evaluation Of Fx-1006a In Patients With V122i Or Wild-Type Transthyretin (TTR) Amyloid Cardiomyopathy

Condition:   TTR-CM
Intervention:   Drug: tafamidis
Sponsor:   Pfizer
Active, not recruiting - verified October 2015

Identification of Risk Factors for Arrhythmia in Children and Adolescents With Hypertrophic Cardiomyopathy

Condition:   Hypertrophic Cardiomyopathy (HCM)
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified January 2012

Transthyretin-Associated Amyloidoses Outcome Survey (THAOS)

Conditions:   Transthyretin Mutations;   Transthyretin Amyloidosis
Intervention:   Other: None. Observational Study.
Sponsor:   Pfizer
Recruiting - verified October 2015

Phenotype/Genotype Correlations in Neuromuscular Disorders

Condition:   Neuromuscular Disease
Sponsor:   National Institute of Neurological Disorders and Stroke (NINDS)
Completed - verified May 2007

Evaluation of Patients With Known or Suspected Heart Disease

Conditions:   Peripheral Artery Disease;   Coronary Disease;   Diabetes and Heart Failure;   Dilated Cardiomyopathy;   Heart Failure;   Renal Artery Stenosis;   Pulmonary Hypertension
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified January 2009

Get CardioSmart

You're Invited